Ombitasvir, paritaprevir and ritonavir)

Red

Brand Name(s):Viekirax

Indication:Hepatitis C – Chronic (CHC) & virus (HCV)

Rationale:1,2,3

Considered:Feb-15

Review Date:Jan-26

Comments:
MHRA Recommend INR monitoring secondary to treatment. 2017

MHRA Recommend screening for Hepatitis B before starting treatment 2017

MHRA state rapid reducion in hepatitis C viral load can affect glucose metabolism in patients with Diabetes 2018

NICE technology appraisal guidance [TA365]
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Full document can be found at: http://www.nice.org.uk/guidance/ta365
November 2015